MEDIUM confidence: 100% data completeness, but the composite (50) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
Avg target $93 (last qtr, 16 analysts) → $89 (last mo, 11) (-3.7%).
Buy-rated share 59% → 59% over ~3 months (+0pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | $1.54 | $1.55 | +0.6% |
| Feb 2026 | $1.34 | $1.36 | +1.5% |
| Nov 2025 | $1.31 | $1.36 | +3.8% |
| Aug 2025 | $1.23 | $1.26 | +2.4% |
| May 2025 | $1.58 | $1.62 | +2.5% |
| Feb 2025 | $1.36 | $1.39 | +2.2% |
| Nov 2024 | $1.25 | $1.26 | +0.8% |
| Aug 2024 | $1.20 | $1.23 | +2.5% |
| Metric (USD) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $31.7B— | $31.2B-1.4% | $32.4B+3.6% | $33.5B+3.6% | $36.4B+8.4% |
| EPS (dil.) | $3.73— | $2.82-24.4% | $2.76-2.1% | $3.61+30.8% | $3.73+3.3% |
| Free Cash Flow | $6.0B— | $4.6B-23.4% | $5.2B+13.5% | $5.2B-0.3% | $5.4B+4.6% |
| Gross Margin | 68.0% | 65.7%-2.3pp | 65.3%-0.3pp | 65.3%-0.0pp | 65.0%-0.3pp |
| Operating Margin | 18.2% | 17.6%-0.6pp | 15.9%-1.7pp | 17.8%+1.9pp | 17.8%+0.0pp |
| Net Margin | 15.9% | 12.0%-3.9pp | 11.4%-0.7pp | 13.9%+2.5pp | 13.2%-0.7pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Net insider -$5.5M over 180 days (0 open-market buys, 7 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
The QScore of 50 for Medtronic indicates a neutral outlook, with the long-term score slightly outpacing the short-term score. Medtronic scores high on profitability and risk, driven by its strong gross margin of 65.0% and low beta of 0.6. However, its growth and momentum categories are weighed down by modest EPS growth of 3.3% and a 12-month return of -5.8%, respectively. The stock trades at a P/E of 21.6, which is relatively in line with its peers, contributing to its mid-range value score.